ES2187832T3 - Metodos y composiciones para estimular el crecimiento de neuritas usando compuestos con afinidad a fkbp12 en combinacion con factores neurotroficos. - Google Patents

Metodos y composiciones para estimular el crecimiento de neuritas usando compuestos con afinidad a fkbp12 en combinacion con factores neurotroficos.

Info

Publication number
ES2187832T3
ES2187832T3 ES97948308T ES97948308T ES2187832T3 ES 2187832 T3 ES2187832 T3 ES 2187832T3 ES 97948308 T ES97948308 T ES 97948308T ES 97948308 T ES97948308 T ES 97948308T ES 2187832 T3 ES2187832 T3 ES 2187832T3
Authority
ES
Spain
Prior art keywords
compositions
growth
neurites
stimulate
fkbp12
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97948308T
Other languages
English (en)
Inventor
Robert E Zelle
Michael Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25009490&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2187832(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2187832T3 publication Critical patent/ES2187832T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A PROCEDIMIENTOS Y A COMPOSICIONES FARMACEUTICAS PARA ESTIMULAR EL CRECIMIENTO DE NEURITOS EN CELULAS NERVIOSAS. LAS COMPOSICIONES COMPRENDEN UNA CANTIDAD NEUROTROFICA DE UN COMPUESTO Y UN FACTOR NEUROTROFICO, TAL COMO EL FACTOR DEL CRECIMIENTO NERVIOSO (NGF). LOS PROCEDIMIENTOS COMPRENDEN EL TRATAMIENTO DE LAS CELULAS NERVIOSAS CON LAS COMPOSICIONES MENCIONADAS O CON COMPOSICIONES QUE COMPRENDAN EL COMPUESTO SIN UN FACTOR NEUROTROFICO. LOS PROCEDIMIENTOS DE LA INVENCION PUEDEN UTILIZARSE PARA PROMOVER LA REPARACION DE LOS DAÑOS NEURONALES PROVOCADOS POR ENFERMEDADES O TRAUMATISMOS FISICOS.
ES97948308T 1996-11-13 1997-11-13 Metodos y composiciones para estimular el crecimiento de neuritas usando compuestos con afinidad a fkbp12 en combinacion con factores neurotroficos. Expired - Lifetime ES2187832T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/748,448 US5811434A (en) 1996-11-13 1996-11-13 Methods and compositions for stimulating neurite growth

Publications (1)

Publication Number Publication Date
ES2187832T3 true ES2187832T3 (es) 2003-06-16

Family

ID=25009490

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97948308T Expired - Lifetime ES2187832T3 (es) 1996-11-13 1997-11-13 Metodos y composiciones para estimular el crecimiento de neuritas usando compuestos con afinidad a fkbp12 en combinacion con factores neurotroficos.

Country Status (21)

Country Link
US (1) US5811434A (es)
EP (1) EP0941112B1 (es)
JP (1) JP2001503777A (es)
KR (1) KR20000068963A (es)
CN (1) CN1239435A (es)
AR (1) AR013873A1 (es)
AT (1) ATE232395T1 (es)
AU (1) AU5439698A (es)
BR (1) BR9712947A (es)
CA (1) CA2270629A1 (es)
CO (1) CO4920219A1 (es)
DE (1) DE69719063T2 (es)
DK (1) DK0941112T3 (es)
EA (1) EA199900462A1 (es)
ES (1) ES2187832T3 (es)
IL (1) IL129556A0 (es)
IN (1) IN183279B (es)
NZ (1) NZ335395A (es)
PL (1) PL333242A1 (es)
WO (1) WO1998020892A1 (es)
ZA (1) ZA9710258B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US6133456A (en) * 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
US6150527A (en) * 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US6242468B1 (en) 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999062880A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
KR20010071920A (ko) 1998-07-17 2001-07-31 개리 이. 프라이드만 뉴우런 성장 및 연장을 자극하는 화합물, 조성물 및 방법
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6399648B1 (en) * 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6228872B1 (en) 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
WO2001002368A1 (en) 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated N-heterocyclic derivatives with neuronal activity
US6734211B1 (en) 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
AU5606400A (en) * 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
MXPA02002578A (es) 1999-09-08 2002-10-23 Guilford Pharm Inc Compuestos de union a ciclofilina no peptidicos, y su uso.
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
ES2269206T3 (es) * 1999-11-12 2007-04-01 Alcon, Inc. Ligandos de neurofilina para tratar trastornos oculares.
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
ATE319712T1 (de) 1999-12-21 2006-03-15 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
JP2003522767A (ja) * 2000-02-11 2003-07-29 バーテックス ファーマシューティカルズ インコーポレイテッド ニューロン損傷の処置または予防のためのピペラジンおよびピペリジン誘導体
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
CA2435829A1 (en) 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
EP1404325A2 (en) * 2001-05-29 2004-04-07 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
WO2003062773A1 (en) * 2002-01-24 2003-07-31 Pei Electronics, Inc. Compact integrated infrared scene projector
KR20040011237A (ko) * 2002-07-29 2004-02-05 김윤희 Ｐｄｇｆ, 그의 유도체 및 약학적으로 허용되는 그의 염을함유하는 신경세포 보호 및 재생용 조성물
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
EP1546103B1 (en) * 2002-10-03 2009-03-18 Vertex Pharmaceuticals Incorporated Piperazine and piperidine derivatives for treatment of neurological diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
IL115685A (en) * 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors

Also Published As

Publication number Publication date
CA2270629A1 (en) 1998-05-22
DE69719063D1 (de) 2003-03-20
IL129556A0 (en) 2000-02-29
DE69719063T2 (de) 2003-07-31
EP0941112A1 (en) 1999-09-15
KR20000068963A (ko) 2000-11-25
DK0941112T3 (da) 2003-05-19
IN183279B (es) 1999-10-30
EA199900462A1 (ru) 2000-02-28
WO1998020892A1 (en) 1998-05-22
CO4920219A1 (es) 2000-05-29
CN1239435A (zh) 1999-12-22
ZA9710258B (en) 1998-05-28
JP2001503777A (ja) 2001-03-21
AR013873A1 (es) 2001-01-31
AU5439698A (en) 1998-06-03
EP0941112B1 (en) 2003-02-12
PL333242A1 (en) 1999-11-22
US5811434A (en) 1998-09-22
BR9712947A (pt) 2000-03-28
ATE232395T1 (de) 2003-02-15
NZ335395A (en) 1999-07-29

Similar Documents

Publication Publication Date Title
ES2187832T3 (es) Metodos y composiciones para estimular el crecimiento de neuritas usando compuestos con afinidad a fkbp12 en combinacion con factores neurotroficos.
CU23213A3 (es) Difenilureas sustituidas con omega-carboxiarilo como inhibidores de raf quinasa
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
AR015105A1 (es) Una composicion que comprende derivados de urea o carbonato y factores neurotroficos para estimular el crecimiento de neuritas en celulas nerviosas y unmedicamento que la comprende
CR8718A (es) Compuesto de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ECSP066421A (es) MODULACION DE LA EXPRESION DE eIF4E
GT200000198A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos.
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
ES2183937T3 (es) Inhibidores de la adhesion celular.
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ES2156934T3 (es) Compuestos que presentan una potente actividad de antagonistas del calcio y de antioxidantes y su utilizacion como agentes citoprotectores.
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
UY28150A1 (es) Agentes terapeuticos
PA8478501A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
ECSP055840A (es) Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor
ES2138518B1 (es) Actividad de inhibidores de enzima rotamasa.
AR047070A1 (es) Derivados de difenilazetidona
SV2002000233A (es) Compuestos, composiciones y metodos para estimular el crecimiento y elongacion neuronal caso # 0081-01-sv
PA8468501A1 (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
AR029941A1 (es) Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
UY26895A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2